“…According to previous studies, S-(−)-lansoprazole is more easily metabolized to pharmacologically inactive 5-hydroxy and sulfone metabolites (Masa, Hamada, Arimori, Fujii, & Nakamo, 2001;Milura et al, 2004). Better yet, R-(+)-lansoprazole elicited enhanced pharmacodynamics activity compared with racemic lansoprazole (Hotha et al, 2012;Kukulka, Eisenberg, & Nudurupati, 2011;Parekh, Oldfield, & Johnson, 2014 10-250 ng/mL) and the use of large volumes of plasma for intricate sample preparations (Cirilli et al, 2009;Jia et al, 2012;Miura, Tada, & Suzuki, 2004). As a consequence of the numerous merits of R-(+)-lansoprazole, such as the slower metabolism, higher plasma concentration, longer elimination half-time and greater systemic exposure, it was developed and approved for marketing as a novel proton-pump inhibitor with the trade name Dexilant in 2009 (Gomes, Cassiano, Pedrazzoli, & Cass, 2010;Hershcovici, Jha, & Fass, 2011;Katsuki, Hamada, Nakamura, Arimori, & Nakano, 2001;Metz, Vakily, & Dixit, 2009).…”